Inactive Instrument

Teva Pharma Ind. Stock price Nyse

Equities

Pharmaceuticals

Sales 2024 * 15.86B Sales 2025 * 16.28B Capitalization 15.82B
Net income 2024 * 420M Net income 2025 * 743M EV / Sales 2024 * 1.92 x
Net Debt 2024 * 14.62B Net Debt 2025 * 12.12B EV / Sales 2025 * 1.72 x
P/E ratio 2024 *
19.5 x
P/E ratio 2025 *
15.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Teva Pharm profit handily beats Q4 estimates, sales jump RE
Sandoz dials up product launch plans ahead of market debut RE
Endo International : Drugmakers, pharmacies next targets for U.S. opioid settlements RE
Endo International : J&J, other drugmakers go to trial in California in $50 billion case over 'deadly legacy' of opioids RE
Exclusive: AbbVie in talks to sell $5 billion women's drugs portfolio - sources RE
ADVANZ PHARMA : Correction to Drugmakers Raise Prices Article of Jan. 1 DJ
Teva Pharmaceutical Industries : , MedinCell Say Results Positive in Risperidone Trial DJ
Pizza-sized boxes and paying a premium: Israel's COVID-19 vaccine rollout RE
Exclusive: Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk RE
Teva Pharmaceutical Industries : Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk RE
Teva Pharmaceutical Industries : Drugmakers agree to halve prices to get on China state insurance list RE
Teva Pharmaceutical Industries : EU fines Teva, Cephalon over pay-for-delay drug deal RE
Teva Pharmaceutical Industries : European Commission Fines Teva, Cephalon EUR60.5 Million for Antitrust Violation DJ
Teva Pharmaceutical Industries : in EU antitrust crosshairs over its Copaxone drug RE
Teva Pharmaceutical Industries : EU antitrust regulators investigating Teva over its Copaxone drug RE
More news
Teva Pharmaceutical Industries Limited is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
More about the company